Dongyang Pharmaceutical (06887) announces 2026 interim results: switching between old and new kinetic energy, innovation engine takes over

Zhitong Finance App learned that on August 31, Dongyang Pharmaceutical (06887) announced the 2026 interim results. During the reporting period, the company achieved a turnover of about 1,075 million yuan, and total losses and overall income attributable to the company's equity holders was about 596 million yuan. Mainly due to fluctuations in the influenza cycle, sales of the core product Covir (oseltamivir phosphate) declined in stages. At the same time, the company's transformation has accelerated markedly: the chronic disease pipeline has been implemented intensively, 6 types of insulin have covered all clinical scenarios, and the new class 1 drug, oproglicin, has been declared in the 2026 national health insurance catalogue; internationalization has achieved a milestone breakthrough; the first domestically produced insulin gansine was approved by the FDA and commercialized delivery in the US, locking in more than 18 million overseas orders; and AI pharmaceuticals have covered the entire process of new drug development. The company said it is currently in the window of transition from “single product drive” to “multi-engine drive” and will adhere to the strategic direction of innovation driven and internationalization.